Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded Access Opens Window For Dose Optimization Studies In Cancer

Executive Summary

The period after completion of pivotal trials but ahead of FDA approval provides an opportunity for oncology drug sponsors to conduct badly needed dose comparison trials, a multi-stakeholder panel says at the annual Conference on Clinical Cancer Research.

You may also be interested in...



Novartis’ Panobinostat Review Pits Progression-Free Survival Against Toxicities

FDA advisory committee will also consider whether appropriate dose was selected for Phase III trial of the oral deacetylase inhibitor in patients with relapsed multiple myeloma.

Dose Finding At Breakthrough Speed: FDA Found A Role For Anecdotal Reports On Zykadia

Review of Novartis’ lung cancer therapy highlights the difficulties of getting traditional dosing work done in the compressed development program of a “breakthrough” drug – and shows just how flexible the agency will be in gathering information for the accelerated programs.

Iclusig Experience Reflects Regulatory Risk Inherent With Accelerated Approval

FDA reviewers and outside experts discussed at length concerns about cardiovascular and other adverse events in the single-arm PACE trial but believed ponatinib’s impressive efficacy in a difficult-to-treat leukemia population warranted bringing the drug to market. Sales of the tyrosine kinase inhibitor were halted less than 11 months later as safety and dosing concerns continued to pile up.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel